Dr. BRIAN MEHLING

M.D. M.S. Founder & Chief Medical Officer of Blue Horizon International.

Dr. Brian Mehling is a board-certified orthopedic trauma surgeon specializing in regenerative medicine, with nearly 25 years of clinical experience. He is board certified by the American Academy of Anti-Aging Medicine and is a Fellow of the American Academy of Orthopaedic Surgeons. Named a 2022 NJ Top Doc, Dr. Mehling is a respected researcher and leads stem cell therapy research at BHI Therapeutic Sciences, Inc. He earned his medical degree from Wright State University and is currently pursuing a PhD in Biochemistry with a focus on stem cell therapy. He currently treats patients throughout Hackensack, New Jersey, and West Islip, New York at Mehling Orthopedics.

The organization is focused on targeting new stem cell therapy treatments and research. Dr. Mehling and his team have recently been notified by the Food and Drug Administration (FDA) that their Investigational New Drug (IND) application to allow for the initiation of a clinical study of FDA-approved cell therapy (HCP, cord blood) for treatment of acute ischemic stroke may proceed.